Loading clinical trials...
Loading clinical trials...
A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders
Conditions
Interventions
Brexpiprazole
Locations
9
United States
Woodland International Research Group
Little Rock, Arkansas, United States
Woodland Research Northwest, LLC
Rogers, Arkansas, United States
Alliance for Wellness dba Alliance for Research
Long Beach, California, United States
New Hope Clinical Research
Charlotte, North Carolina, United States
IPS Research Company
Oklahoma City, Oklahoma, United States
Cutting Edge Research Group
Oklahoma City, Oklahoma, United States
Start Date
October 10, 2017
Primary Completion Date
May 21, 2018
Completion Date
May 21, 2018
Last Updated
June 12, 2018
NCT06066983
NCT07540338
NCT07494305
NCT07533331
NCT07439276
NCT04631042
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions